Manhattan Mental Health Counseling launches Progress Pathways, a new initiative to track progress and growth in therapy
Manhattan Mental Health Counseling (MMHC) launches Progress Pathways, an innovative new way for clients to track growth in therapy.
New York, June 26, 2025 -- Manhattan Mental Health Counseling has launched Progress Pathways, a new initiative designed to help active clients mark their progress and stay motivated in therapy over time.
Progress Pathways introduces a five-level framework tied to consistent therapy attendance and engagement. As clients continue to show up and work on themselves, they unlock messages, badges, and trophies. These milestones are designed to acknowledge commitment and dedication, spark reflection and encourage continued progress. The new scheme is a light structure that reinforces the often slow and steady nature of emotional growth.
Steven Buchwald, managing director of Manhattan Mental Health Counseling, shared, 'We're here to help people move forward — with dignity, with agency, and with tools that last. Progress Pathways reinforces that therapy isn't just about showing up — it's about building something over time. This program turns that progress into something you can actually see and feel.'
While not tailored to individual treatment plans, Progress Pathways helps clients stay oriented in their journey and recognize that forward motion is happening. The new program reflects the practice's commitment to practical, ethically grounded support that strengthens engagement.
Progress Pathways is part of a growing movement to make therapy not only more accessible but also more meaningful. It is a motivational support program designed to complement, but not replace, personalized treatment plans. All treatment decisions remain the responsibility of each client's licensed therapist.
The goal is to use Progress Pathways alongside individualized therapy plans to turn growth into visible, tangible, measurable wins, encouraging clients to celebrate milestones and achievements one step at a time and continue on their journey. By accessing the program, clients can unlock badges and trophies and monitor how close they are to their next milestone via progress bars. Each client can use the initiative like a transformation roadmap, which helps them get closer to their final destination.
About Manhattan Mental Health Counseling
Manhattan Mental Health Counseling is an established provider of online mental health services, which strives to make effective, personalized therapy accessible to all. Founded by Natalie Buchwald, LMHC, MMHC delivers mental health counseling across New York State and New Jersey. The mission is to empower individuals and build mental resilience to help clients live their lives with renewed energy, enthusiasm, strength, and purpose. MMHC has a dedicated team of experienced, licensed therapists.
The recent launch of Progress Pathways marks an exciting milestone for MMHC, with clients now able to track growth by unlocking levels and gaining recognition of achievements and progress. A simple, effective roadmap, the program is designed to encourage continued commitment, inspire and motivate individuals to work towards the next milestone, and help them celebrate growth.
Anyone who would like to learn more about Manhattan Mental Health Counseling is encouraged to make use of the following contact details:
Contact Info:
Name: Steven Buchwald
Email: Send Email
Organization: Manhattan Mental Health Counseling
Address: 303 Fifth Avenue Suite 1108, New York, NY 10016
Phone: 212-960-8626
Website: https://manhattanmentalhealthcounseling.com
Release ID: 89163189
In case of identifying any problems, concerns, or inaccuracies in the content shared in this press release, or if a press release needs to be taken down, we urge you to notify us immediately by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will be readily accessible to address your concerns and take swift action within 8 hours to rectify any issues identified or assist with the removal process. We are committed to delivering high-quality content and ensuring accuracy for our valued readers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
2 Mooning Stocks with Promising Prospects and 1 to Approach with Caution
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions. But not every company with momentum is a long-term winner, and plenty of investors have lost money betting on short-term fads. Keeping that in mind, here are two stocks we think live up to the hype and one that may correct. One-Month Return: +8.1% With over 9,000 retail pharmacy locations serving as neighborhood health destinations across America, CVS Health (NYSE:CVS) operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance through its Aetna subsidiary. Why Does CVS Give Us Pause? Sizable revenue base leads to growth challenges as its 7% annual revenue increases over the last two years fell short of other healthcare companies Estimated sales growth of 2.5% for the next 12 months implies demand will slow from its two-year trend Earnings per share fell by 2.9% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable CVS Health's stock price of $66.33 implies a valuation ratio of 10.8x forward P/E. If you're considering CVS for your portfolio, see our FREE research report to learn more. One-Month Return: +14.1% Founded in 1993 by Jensen Huang and two former Sun Microsystems engineers, Nvidia (NASDAQ:NVDA) is a leading fabless designer of chips used in gaming, PCs, data centers, automotive, and a variety of end markets. Why Will NVDA Outperform? Market share has increased this cycle as its 140% annual revenue growth over the last two years was exceptional Share repurchases have amplified shareholder returns as its annual earnings per share growth of 80.2% exceeded its revenue gains over the last five years Robust free cash flow margin of 48.8% gives it many options for capital deployment, and its growing cash flow gives it even more resources to deploy At $154.60 per share, Nvidia trades at 32.7x forward P/E. Is now the time to initiate a position? Find out in our full research report, it's free. One-Month Return: +4.2% A developer of the communication systems used in the Batmobile of 'The Dark Knight,' ESCO (NYSE:ESE) is a provider of engineered components for the aerospace, defense, and utility sectors. Why Does ESE Catch Our Eye? Demand for the next 12 months is expected to accelerate above its two-year trend as Wall Street forecasts robust revenue growth of 18.2% Offerings are difficult to replicate at scale and result in a stellar gross margin of 38.9% Earnings per share grew by 20.7% annually over the last two years and trumped its peers ESCO is trading at $190.33 per share, or 30.7x forward P/E. Is now the right time to buy? See for yourself in our in-depth research report, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as ServiceNow (+178% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Fetch pet insurance review 2025
Fetch pet insurance rating: 1 out of 5 stars Fetch has relatively generous coverage, but unfortunately, its rating in our evaluation was brought down by its extremely high cost: It was by far the most expensive pet insurance policy for $5,000 in annual coverage in our evaluation. Ultimately, you can get much more value with other pet insurers that offer good coverage at competitive rates. One upside to Fetch is that if your pet has a curable preexisting injury or illness and goes 12 months without signs, symptoms, or treatment, the condition is eligible for coverage. This can include problems such as respiratory infections and diarrhea. Another upside, if you choose to pay the high price for Fetch, is that policies include a range of small coverage types: Payment for advertising and a reward if your pet is lost or stolen Reimbursement for kennel costs if you're hospitalized Reimbursement of the price you paid for the pet if the pet dies Coverage for lost travel costs if you have to cancel a vacation because your pet becomes sick or injured Learn more: How does pet insurance work? A complete guide. Pros Covers dental illness Covers acupuncture and chiropractic care Reimburses for a range of smaller costs, such as advertising and rewards Cons Very high average cost Maximum annual coverage of $15,000 No multi-pet discount If your pet has not been to the vet six months before the start of your policy, an exam is required within 30 days of the policy effective date Fetch pet insurance basics Annual maximum limit choices: $5,000, $10,000, $15,000 Deductible choices: $300, $500, $700 Reimbursement choices: 70%, 80%, 90% Fetch waiting periods For accident coverage: 15 days For illness coverage: 15 days Special waiting period: 6 months for cruciate ligament problems, patella issues, and hip dysplasia Fetch age restrictions for buying a new policy Minimum pet age: 6 weeks Maximum pet age: None Fetch sells an accident and illness policy and a wellness plan. Fetch pet insurance provides a solid range of coverage, without the need to pay for add-ons. Fetch covers: The vet exam fee Hereditary and congenital conditions Diagnostics such as X-rays and ultrasounds Dental accidents and illnesses Behavioral therapy for conditions such as aggression, separation anxiety, and phobias Alternative therapy, such as acupuncture and chiropractic care Prescription drugs and supplements Up to $1,000 for pet telehealth visits Advertising/reward for lost/stolen pets Kennel costs if the owner is hospitalized Cost of pet if the pet dies Vacation cancellation costs due to pet illness or injury Learn more: Your guide to what pet insurance covers Fetch offers three wellness plans: Essentials, Advantage, and Prime. Prime provides the most comprehensive coverage and is, therefore, the most expensive option. Essentials: Covers up to $315 in annual care costs starting at $10/month Advantage: Covers up to $520 in annual care costs starting at $20/month Prime: Covers up to $735 in annual care costs starting at $30/month Learn more: Why a pet wellness plan is worth considering All three plans will reimburse you up to specified limits for the following: Annual exam Blood test Dental cleaning Heartworm tests Heartworm, flea, and tick prevention Spaying/neutering Urinalysis and fecal test Vaccinations The Advantage and Prime plans cover anal gland expression and microchipping. The Prime plan also covers a behavioral exam, activity monitor, and health certificate. Learn more: Does pet insurance cover vaccines? Fetch does not cover preexisting conditions. A preexisting condition is defined as an illness, injury, or condition that your pet has shown signs of or that you or your veterinarian noticed before you enrolled, your policy took effect, or during the waiting period for coverage. However, Fetch does cover curable preexisting conditions that go without signs, symptoms, or treatment for 12 months. Examples include broken bones, respiratory infections, and urinary tract infections. Learn more: Pet insurance that covers preexisting conditions Fetch pet insurance does not include access to a 24/7 vet helpline. Fetch policies don't cover the following expenses: Bathing, unless medically necessary Boarding and travel expenses Breeding and pregnancy Cremation Degenerative disorders, including cruciate ligament disease Elective procedures, including tail docking and ear cropping Euthanasia, unless recommended by a veterinarian Experimental treatments Grooming Injury or illness related to abuse, neglect, racing, organized fighting, occupational use of a pet Obedience or training classes Preexisting and bilateral conditions, even if they appear on the other side of the body Preexisting intervertebral disk disease Prescription food Preventive care Weight-loss treatment Yes, but there are restrictions if you want to increase your coverage. All requests for changes in coverage must be made in writing or with verbal confirmation. Increases. You can apply to increase your policy coverage – or decrease your deductible or co-pay – only if you haven't submitted any claims. In most states, you can only apply to increase your coverage once a year when your policy renews. Increasing your coverage will reset your waiting period and preexisting coverage exclusions. Decreases. You can apply to decrease your coverage – or increase your deductible or co-pay – at any time. Fetch had the highest-priced policy in our evaluation of policies with a $5,000 annual coverage limit. Fetch pet insurance came in at 55% above the average cost in our analysis. Learn more: Is pet insurance worth it? How to decide. Fetch does not offer a multi-pet discount. Most pet insurance companies provide a discount of 5% or 10% for insuring multiple pets. No, you must pay your vet and submit a claim to be reimbursed. However, if you expect a large bill, contact Fetch in advance to ask if it will make a special arrangement to pay the vet directly. Learn more: Pet insurance that pays the vet directly: How does it work? Here's what to know about filing a claim with Fetch: To make a claim: Submit a detailed invoice showing your balance was paid in full and medical records from your pet's most recent vet visit. To submit claims quickly: Upload documents through your online account or use the Fetch app. To receive reimbursements faster: Set up direct deposit to be paid five to 10 days faster than by check. If your claim is denied: You can appeal in writing within 90 days of denial of a claim. You must submit a claim within 90 days after a vet visit. Fetch says that it processes claims within 15 days and, once a claim is approved, makes payments in as few as two days if you have direct deposit. Fetch's mobile app is highly rated, but it may not offer as many features as some other pet insurance apps. The Fetch app can be used to upload records, submit claims, track the status of claims, and set up direct deposit. Fetch's mobile app ratings: Apple App store: 4.8 out of 5 stars Google Play store: 4.7 out of 5 stars Fetch pet insurance is available in all 50 states, the District of Columbia and Canada. Yes, Fetch requires that your pet get a medical exam within six months before enrollment. You can contact Fetch by phone, email, mail, and interactive chat on its website. Contact the Fetch sales team at 1-866-984-0104 from 8 a.m. to 9 p.m. ET Monday through Friday and 9 a.m. to 7 p.m. ET on Saturday Contact the Fetch service team at 1-866-467-3875 Monday through Friday from 9 a.m. to 6 p.m. ET The email address is info@ The mailing address is Fetch, P.O. Box 1489, Bolingbrook, IL 60440 The interactive chat is at You can cancel a policy at any time by calling or emailing Fetch. If you cancel a policy within 30 days and haven't filed any claims, you will receive a full refund. After 30 days, your refund will be pro-rated based on the date of termination. Tim Manni edited this article.
Medscape
an hour ago
- Medscape
Semaglutide Benefits Adults With Type 1 Diabetes + Obesity
CHICAGO — Once-weekly semaglutide improved glycemia and reduced weight without increasing hypoglycemia in adults with type 1 diabetes (T1D) and obesity, new research presented at the American Diabetes Association (ADA) 85th Scientific Sessions found. The study results were simultaneously published in NEJM Evidence . 'Semaglutide was effective in lowering or improving time in range, without increasing time below range; it produced weight loss of at least 5%; and it was very safe,' said lead investigator Viral N. Shah, MD, professor of medicine and director of diabetes clinical research at the Center for Diabetes and Metabolic Diseases, Indiana University, Indianapolis. 'We didn't find any difference in severe hypoglycemia between semaglutide and a placebo, and we did not find any [diabetic ketoacidosis] in the entire study,' Shah told Medscape Medical News . 'I think the results are very encouraging, and I hope that industry will take it on and do a regulatory approval trial for semaglutide in type 1,' he added. Over a Third Met Composite Endpoint The 26-week ADJUST-T1D randomized clinical trial investigated semaglutide vs placebo in 72 adults with T1D and obesity (BMI ≥ 30) who were using automated insulin delivery (AID) systems. The trial was investigator-initiated and funded by Breakthrough T1D, not Ozempic manufacturer Novo Nordisk, although the company did provide the drug. A total of 72 patients were randomized 1:1 to receive once-weekly semaglutide, up to 1 mg, or placebo for 26 weeks. Participants had a mean age of 40 years, a mean diabetes duration of 23 years, a mean baseline A1c of 7.8, BMI 35, and body weight 102 kg. Two thirds were using the Tandem Control IQ AID system. The primary endpoint was a composite of continuous glucose monitoring (CGM)-based time in range 70-180 mg/dL of > 70%; time below 70 mg/dL of < 4%; and ≥ 5% weight reduction. A total of 13 of the 36 (36.1%) in the semaglutide group vs zero in the placebo group met the composite endpoint. The between-group difference was 36 percentage points ( P < .001). Semaglutide treatment was associated with a nearly eightfold better chance of achieving the primary outcome (odds ratio, 7.77). Among the secondary outcomes, A1c reductions from baseline to week 26 were 0.7 with semaglutide vs 0.4 with placebo; increased percent time in range was 11.1% vs 2.3%; reductions in CGM mean glucose were 15.7 mg/dL vs 3.6 mg/dL; and reductions in percentage time above 180 mg/dL were 11.1% vs 2.7%. All of those differences were significant, Shah reported. The percentage of time spent below 70 mg/dL from baseline was low and the change from baseline didn't differ significantly between the two groups, 0.1% vs 0.4%. Body weight change at 26 weeks were reductions of 9.2 kg vs 0.4 kg, and BMI drops were 3.3 vs 0.2. Those differences were also significant, Shah said. Daily insulin requirements from baseline to week 26 were reduced significantly by 22.3 units per day with the semaglutide group compared to the placebo group. A total of 57 gastrointestinal events were reported by 19 patients in the semaglutide group vs 13 gastrointestinal events were reported by 9 patients in the placebo group. Two from each group experienced severe hypoglycemia. There were no diabetic ketoacidosis events in either group. The number of people who discontinued the trial early due to persistent gastrointestinal adverse events was three in the placebo group vs two in the semaglutide group. 'Prohibitively Expensive for Those With T1D' Asked to comment, Nicholas B. Argento, MD, senior clinical endocrinologist and diabetes technology director at the Maryland Endocrine and Diabetes Center, Columbia, Maryland, said that the trial 'was small but showed the benefit of using adjunctive therapy in T1D.' There is an 'unmet need' in patients with T1D with a high BMI and suboptimal glycemic control, he told Medscape Medical News Despite proven cardiorenal benefits of both GLP-1 agonists and SGLT2 inhibitors in type 2 diabetes, 'none are approved for use in T1D, which means that they are generally not covered by insurance.' These medications 'end up being prohibitively expensive for those withT1D to access,' Argento noted. But there is no reason to believe we would not see similar benefits in those with T1D, who have a very high cardiorenal risk, he said. 'ADJUST-T1D shows that T2D agents like semaglutide can definitely benefit T1Ds with no safety concerns.' For the time being, Shah pointed to this section of the ADA Standards of Care that was just added in the 2025 edition: A diagnosis of type 1 diabetes does not preclude also having features classically associated with type 2 diabetes (eg, insulin resistance, obesity, and other metabolic abnormalities), and until more precise subsets are used in clinical practice, it may be appropriate to categorize such an individual as having features of both type 1 and type 2 diabetes to facilitate access to appropriate treatment (eg, glucagon-like peptide 1 receptor agonist [GLP-1 RA] or sodium–glucose cotransporter 2 [SGLT2] inhibitor therapies for potential weight and other cardiometabolic benefits) and monitoring systems. 'We use that language from the Standards of Care in prior authorization,' Shah told Medscape Medical News . Independent Industry Consultant Charles Alexander, MD, told Medscape Medical News , 'This small study is very encouraging but unlikely to lead to [US Food and Drug Administration] approval for semaglutide in T1D. In contrast, two much larger currently recruiting global studies of tirzepatide in T1D NCT06914895 and NCT06962280 are more likely to lead, if successful, to FDA approval.' Shah received research support from, does consulting, speaking, and/or serves on advisory boards for Alexion, Novo Nordisk, Dexcom, Enable Bioscience, Zucara Therapeutics, Lilly, Breakthrough T1D, NIH, Insulet, Tandem Diabetes Care, Medtronic, Ascensia Diabetes Care, Embecta, Sanofi, Sequel Med Tech, Biomea Fusion, Lumosfit, and Genomelink. Argento has consulted or been on advisory boards for Eli Lilly Diabetes, Dexcom, DiabeLoop, ConvaTec, and Senseonics and served on the speakers' bureaus for Boehringer-Ingelheim, Dexcom, Eli Lilly Diabetes, MannKind, Novo Nordisk, Xeris, and Zealand Pharmaceuticals. Alexander had no disclosures.
